Our lead candidate, OKI-179, is a novel oral Class I histone deacetylase (HDAC) inhibitor for the treatment of a wide range of solid and hematological malignancies. HDAC inhibitors have shown great promise in preclinical models, however they have had little success treating solid tumors, often due to poor tolerability, inappropriate dosing regimens, poorly conceived combinations, and a lack of stratifying biomarkers. OKI-179 is designed to have improved potency, selectivity, tolerability, as well as easy combinability to overcome the historic limitations of other HDAC inhibitors. OnKure is currently conducting a Phase 1b/2 proof-of-concept trial of OKI-179 in combination with binimetinib in patients with NRAS mutant melanoma.


Candidate Program Cand Prog
Indication Target Ind Target
Discovery HIT I.D. Discov HIT I.D.
Phase 1 HIT to Lead Ph 1 HIT-Lead
Phase 2 Lead Optimization Ph 2 Lead Opt
Pivotal Trial IND Enabling Pivotal IND
NRAS Melanoma Combo w/Binimetinib*
NRAS Melanoma Combo w/Binimetinib*
Nautilus Trial
Class I HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.

*Supply agreement with Pfizer logo; OnKure retains 100% commercialization rights

Histone Deacetylase Inhibition

Histones are proteins that associate with DNA and play an important role in gene regulation and DNA replication. Histone deacetylases, also known as HDACs, are a family of enzymes that remove acetal groups from histones and cytoplasmic proteins to regulate gene transcription and protein activity, respectively. Unlike normal cells, cancer cells may lack multiple epigenetic regulatory mechanisms and therefore, when HDACs are inhibited, it results in tumor cell cycle arrest, differentiation and apoptosis.

OKI-179 specifically inhibits Class I HDACs and causes the hyperacetylation of histones. This over acetylation activates transcription and triggers the production of proteins that have been downregulated. Importantly, many of these down-regulation events are used by cancer cells to escape from anti-cancer therapy. Thus, combining OKI-179 with targeted therapies is predicted to be more effective than using those therapies in isolation.

Our Targets

OnKure has selected and is exploring several oncology targets to expand its growing pipeline, with the goal of filing two or more INDs in the next three years. These biologically validated drivers of cancer have been chosen based on the following criteria:

Cell Cycle Biology icon

Ability to leverage our team’s expertise in kinase inhibition, cell cycle biology, signal transduction, epigenetics, and oncogenic pathway destabilization

target icon

Target structure can be determined (structural enablement)

biological validation icon

Compelling biological validation

shield icon

Potential for best-in-class drug candidate

clinical proof of concept path icon

Focused clinical proof of concept path identified

synergy icon

Opportunity for portfolio synergy